Compare Moody's Corporation (MCO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Moody's Corporation trades at $473 (market cap $80.14B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Moody's Corporation is far larger — about 82× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MCO | MRVI | |
|---|---|---|
Market Cap | $80.14B | $977.37M |
Volume | 829,155 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $539.61 | $9.00 |
52-Week Low | $412.23 | $2.83 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.17B | $1.08B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $464.13, down 1.35% today, but maintains a bullish technical outlook with strong support at $464. Revenue grew to $7.72B in 2025 with a net income margin of 34.25%, and the company has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic moves like a minority stake in PhilRatings to bolster Asia-Pacific presence and a top RiskTech100 ranking for the fifth year.
The outlook remains positive with a consensus price target of $536.40, implying 15.6% upside, supported by robust profitability and growth initiatives. Key risks include high valuation multiples and exposure to economic cycles affecting credit demand. Analyst sentiment is predominantly bullish with 18 buy ratings.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
